Katy Marshall

DocwireNews

A multicenter clinical trial compared the efficacy of 2-dimensional (2D) and 3-dimensional (3D) contrast-enhanced (CE) ultrasonography (US) evaluations with the current clinical standard of CE magnetic resonance imaging (MRI) or computed tomography (CT) in detecting residual viable hepatocellular carcinoma following transarterial chemoembolization (TACE).
Although research exists on the diagnostic performance of 2D and 3D CE US compared with CE MRI or CT, investigators determined that a multicenter trial was necessary.
Eligible patients over 21 years of age underwent baseline 2D and 3D CE US before receiving TACE and 1 to 2 weeks and/or 4 to 6 weeks after TACE. The patients also received CE MRI or CT 4 to 6 weeks after TACE.
Three fellowship-trained radiologists evaluated CE US and CE MRI or CT for residual viable tumors and compared the results with reference standards of pathology (18%), angiography following re-treatment after discovery of residual disease at 1- to 2-month follow-up imaging (31%), CE MRI or CT at 4 to 8 months follow-up (42%), or CE MRI or CT if clinically decompensated with a viability higher than 50% (9%).
Of the 132 eligible patients, 87 were male and 45 were female. The average patient age was 64 years.
Four to 6 weeks after patients received TACE, the sensitivity of 2D CE US was 91% (95% Cl, 84-95), higher than CE MRI or CT at 68% (95% Cl, 58-76; P&lt;.001). Following the same time frame, 3D CE US sensitivity was 89% (95% Cl, 81-94), also higher than CE MRI or CT.
However, at 4 to 6 weeks, the specificity of CE MRI or CT at 85% (95% Cl, 76-91) was higher than 2D CE US at 70% (95% Cl, 56-80) and 3D CE US at 67% (95% Cl, 53-78).
For 2D CE US, the researchers observed no differences in diagnostic criteria between 1 to 2 weeks and 4 to 6 weeks.

Brandon Twyford

POLAR: Pembrolizumab, Olaparib Extends Survival for Select Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

Liquid Biopsy-Guided Cetuximab Rechallenge Demonstrates Improved Response, Disease Control Rates for mCRC

Colorectal Cancer

Rob Dillard

Identification and Diagnosis of Possible Mutations in Human p53 Lymphocytes in Patients With B-cell CLL

Oncology

Latest News

Contrast-Enhanced US Evaluations Show Promise in Identifying Hepatocellular Carcinoma Tumors

Hepatocellular Carcinoma

Radiologists evaluated CE US and CE MRI or CT for residual viable HCC tumors and compared the results. 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe